Donoghue Forlines
ABBV icon

Donoghue Forlines’s AbbVie ABBV Stock Holding History

Donoghue Forlines’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.12M Buy
11,936
+4,245
+55% +$1.09M 0.79% 55
2026
Q2 		$1.94M Buy
7,691
+377
+5% +$81.1K 0.5% 60
2026
Q1 		$1.59M Sell
7,314
-872
-11% -$193K 0.44% 93
2025
Q4 		$1.87M Buy
8,186
+1,157
+16% +$264K 0.58% 58
2025
Q3 		$1.63M Sell
7,029
-664
-9% -$135K 0.5% 59
2025
Q2 		$1.43M Sell
7,693
-9,791
-56% -$1.82M 0.41% 95
2025
Q1 		$3.66M Buy
17,484
+8,462
+94% +$1.65M 1.16% 12
2024
Q4 		$1.6M Buy
9,022
+1,131
+14% +$208K 0.54% 55
2024
Q3 		$1.56M Buy
7,891
+276
+4% +$51.5K 0.44% 54
2024
Q2 		$1.31M Buy
7,615
+118
+2% +$19.5K 0.37% 76
2024
Q1 		$1.37M Buy
7,497
+1,398
+23% +$241K 0.39% 79
2023
Q4 		$945K Sell
6,099
-216
-3% -$31.5K 0.3% 89
2023
Q3 		$941K Buy
6,315
+641
+11% +$94.1K 0.34% 91
2023
Q2 		$764K Buy
5,674
+2,322
+69% +$341K 0.24% 94
2023
Q1 		$534K Sell
3,352
-186
-5% -$28.4K 0.19% 127
2022
Q4 		$572K Sell
3,538
-1,132
-24% -$174K 0.2% 149
2022
Q3 		$627K Sell
4,670
-7,579
-62% -$1.09M 0.23% 79
2022
Q2 		$1.88M Sell
12,249
-3,877
-24% -$592K 0.49% 30
2022
Q1 		$2.61M Buy
16,126
+3,089
+24% +$449K 0.57% 29
2021
Q4 		$1.76M Sell
13,037
-1,732
-12% -$205K 0.3% 79
2021
Q3 		$1.59M Buy
14,769
+64
+0.4% +$7.31K 0.31% 83
2021
Q2 		$1.66M Buy
14,705
+340
+2% +$38.3K 0.31% 84
2021
Q1 		$1.56M Sell
14,365
-842
-6% -$90.1K 0.3% 83
2020
Q4 		$1.63M Buy
+15,207
New +$1.46M 0.31% 54
2020
Q1 		– Sell
-25,185
Closed -$2.23M – 61
2019
Q4 		$2.23M Buy
+25,185
New +$2.09M 0.35% 110
2018
Q1 		– Sell
-27,236
Closed -$2.63M – 143
2017
Q4 		$2.63M Sell
27,236
-188,545
-87% -$17.8M 0.2% 88
2017
Q3 		$19.2M Sell
215,781
-14,477
-6% -$1.1M 2.02% 7
2017
Q2 		$16.7M Buy
+230,258
New +$15.5M 1.89% 10

Other funds holding ABBV

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Donoghue Forlines's ABBV Position: Q3 2026 in Review

Donoghue Forlines increased its AbbVie (ABBV) stake by 55% in Q3 2026, buying an estimated $1.09M and bringing the position to 11,936 shares worth $3.12M. The position accounts for 0.79% of the portfolio, ranked #55.

Donoghue Forlines first reported a position in ABBV in Q2 2017 and has held it in 28 quarters since. The position peaked at $19.2M in Q3 2017. 2,709 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Donoghue Forlines held 11,936 shares of AbbVie worth $3.12M as of Q3 2026.
  • Donoghue Forlines bought 4,245 AbbVie shares in Q3 2026, an estimated $1.09M.
  • AbbVie made up 0.79% of Donoghue Forlines's portfolio in Q3 2026, its #55 holding.
  • Donoghue Forlines first reported a position in AbbVie in Q2 2017 and has held it in 28 quarters since.
  • Donoghue Forlines's AbbVie position peaked at $19.2M in Q3 2017.
  • 2,709 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Donoghue Forlines's 13F filing for Q3 2026, filed 2 Nov 2026.